Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | METAP2 | P50579 | 2/20 | 0.46 |
| ▸ | METAP1 | P53582 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6456277 | 1.00 | SLC6A4 (0.46) | SLC6A4SLC6A3SLC6A2METAP2METAP1 | |
| SCHEMBL6457746 | 0.80 | HIF1A (0.41) | ALDH1A1GAA | |
| SCHEMBL6924088 | 0.80 | HIF1A (0.41) | ALDH1A1GAA | |
| SCHEMBL6463057 | 0.80 | HIF1A (0.41) | ALDH1A1GAA | |
| SCHEMBL517632 | 0.76 | ALOX5 (0.41) | SLC6A4SLC6A3SLC6A2ALOX5ALDH1A1 | |
| SCHEMBL2432421 | 0.76 | KDM4E (0.43) | ALOX5ALDH1A1LMNA | |
| SCHEMBL9310267 | 0.71 | SLC6A4 (0.45) | SLC6A4SLC6A3SLC6A2METAP2METAP1 | |
| SCHEMBL1285411 | 0.71 | ALDH1A1 (0.51) | ALOX5ALDH1A1AURKARPS6KB1AURKB | |
| SCHEMBL6894430 | 0.71 | ALDH1A1 (0.51) | ALOX5ALDH1A1AURKARPS6KB1AURKB | |
| SCHEMBL6897764 | 0.71 | ALDH1A1 (0.51) | ALOX5ALDH1A1AURKARPS6KB1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | SLC6A4 205/4885SLC6A3 144/4885SLC6A2 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.